Inspire Medical Systems (INSP) EBITDA (2017 - 2026)

Inspire Medical Systems has disclosed EBITDA across 10 years of filings, most recently posting -$514000.0 for Q2 2026.

• In Q2 2026, EBITDA rose 84.5% year-over-year to -$514000.0; the TTM figure through Jun 2026 stood at $54.1 million (up 30.73% YoY), while the FY2025 annual figure was $51.0 million, up 41.21% from the prior year.
• EBITDA came in at -$514000.0 for Q2 2026 at Inspire Medical Systems, up from -$1.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $46.1 million in Q4 2025 to a low of -$19.5 million in Q1 2023.
• Average EBITDA over 5 years is -$136555.6, with a median of -$1.3 million recorded in 2025.
• Year-over-year, EBITDA surged 2875.22% in 2023 and tumbled 165.03% in 2025.
• Over 5 years, EBITDA stood at -$335000.0 in 2022, then surged by 2875.22% to $9.3 million in 2023, then soared by 242.95% to $31.9 million in 2024, then surged by 44.62% to $46.1 million in 2025, then sank by 101.11% to -$514000.0 in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$514000.0 in Q2 2026, -$1.1 million in Q1 2026, and $46.1 million in Q4 2025.